GE9 Stock Overview
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
GE9 passed our risk checks.
Genmab A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr.265.50 |
52 Week High | kr.393.50 |
52 Week Low | kr.246.70 |
Beta | 0.78 |
1 Month Change | -3.45% |
3 Month Change | 5.02% |
1 Year Change | -28.97% |
3 Year Change | -13.74% |
5 Year Change | 77.53% |
Change since IPO | 721.98% |
Recent News & Updates
Recent updates
Shareholder Returns
GE9 | DE Biotechs | DE Market | |
---|---|---|---|
7D | -0.8% | -3.1% | 1.8% |
1Y | -29.0% | -22.4% | 2.2% |
Return vs Industry: GE9 underperformed the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: GE9 underperformed the German Market which returned 2.2% over the past year.
Price Volatility
GE9 volatility | |
---|---|
GE9 Average Weekly Movement | 4.4% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GE9 has not had significant price volatility in the past 3 months.
Volatility Over Time: GE9's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 2,204 | Jan G.J. van Winkel | www.genmab.com |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies.
Genmab A/S Fundamentals Summary
GE9 fundamental statistics | |
---|---|
Market cap | €17.46b |
Earnings (TTM) | €583.31m |
Revenue (TTM) | €2.21b |
29.9x
P/E Ratio7.9x
P/S RatioIs GE9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GE9 income statement (TTM) | |
---|---|
Revenue | kr.16.47b |
Cost of Revenue | kr.226.00m |
Gross Profit | kr.16.25b |
Other Expenses | kr.11.90b |
Earnings | kr.4.35b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
Earnings per share (EPS) | 67.10 |
Gross Margin | 98.63% |
Net Profit Margin | 26.42% |
Debt/Equity Ratio | 0% |
How did GE9 perform over the long term?
See historical performance and comparison